TAE Life Sciences, a pioneer in advancing Boron Neutron Capture Therapy (BNCT) for cancer treatment, proudly announces it has earned the 2023 Biotech Breakthrough Award for Oncology Innovation of the Year.
Anthony
The Promise of Biologically Targeted Brain Cancer Treatment
How BNCT will improve outcomes for the most difficult-to-treat cancers
TAE Life Sciences Earns Oncology Innovation of the Year Award
TAE Life Sciences, a pioneer in advancing Boron Neutron Capture Therapy (BNCT) for cancer treatment, proudly announces it has earned the 2023 Biotech Breakthrough Award for Oncology Innovation of the Year.
Study Published in the Journal of Medicinal Chemistry Shows TAE Life Sciences’ BTS Drug Offers Many Advantages Over BPA for BNCT Use
The team at TAE Life Sciences is thrilled to unveil groundbreaking research that could transform the landscape of cancer care. A recent study, focusing on TAE Life Sciences’ Boronotyrosine (BTS) drug, a novel borylated amino acid analogue, has demonstrated exceptional potential to elevate the effectiveness of BNCT in combating cancer.
TAE Life Sciences Celebrates Collaboration Milestones and Unveils Alphabeam for in-hospital BNCT at ASTRO 2023 Annual Meeting
TAE Life Sciences, a pioneer in advancing Boron Neutron Capture Therapy (BNCT) for cancer treatment, is thrilled to announce it is bringing BNCT to this year’s annual meeting of the American Society for Radiation Oncology (ASTRO) in San Diego.
Novel Particle Therapy Whitepaper
Dramatic advances in cancer treatment have completely transformed the landscape of cancer care in the last several decades.